Skip to main content
Article
Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors
Faculty of Health and Behavioural Sciences - Papers (Archive)
  • Kelly A Newell, University of Wollongong
  • Xu-Feng Huang, University of Wollongong
  • Chao Deng, University of Wollongong
  • Teresa M Du Bois, University of Wollongong
  • Mei Han, University of Wollongong
RIS ID
25056
Publication Date
1-1-2009
Publication Details

du Bois, T., Newell, K., Han, M., Deng, C. & Huang, X. (2009). Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33 (1), 37-40.

Abstract

Perinatal phencyclidine (PCP) treatment has been used to model brain pathological processes that may be present in schizophrenia such as increased apoptosis during early brain development, and long-term alterations in expression of parvalbumin-containing interneurons and glutamatergic N-methyl-d-aspartate (NMDA) receptors. We report that this treatment also affects receptor expression of another excitatory neurotransmitter receptor, the muscarinic receptor. Female rat pups received injections of the NMDA receptor antagonist PCP (10 mg/kg, s.c.) or saline on postnatal days (PN)7, 9 and 11. [3H]Pirenzepine binding to M1/4 receptors was examined at four time-points (PN12, 18, 32 and 96) following treatment cessation. Significant effects of treatment on [3H]pirenzepine binding were evident immediately after treatment cessation with a decrease in PCP-treated rats at PN12 in the prefrontal cortex (− 24%, p < 0.05) and hippocampus (− 19%, p < 0.05). After this initial decrease, binding subsequently increased to 47% above control levels in the prefrontal cortex of adolescent animals, which remained elevated in adulthood (+ 10%, p < 0.05), while in the hippocampus there was a trend towards increased binding in adolescent animals and no change thereafter. This work adds to findings demonstrating that perinatal PCP exposure leads to long-term imbalance of excitatory and inhibitory neurotransmitter systems, supporting its relevance as a developmental model of schizophrenia pathology. Alterations in muscarinic receptor expression may contribute specifically to the cognitive impairments reported to occur after perinatal NMDA receptor antagonist treatment.

Grant Number
NHMRC/573426
Citation Information
Kelly A Newell, Xu-Feng Huang, Chao Deng, Teresa M Du Bois, et al.. "Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors" (2009) p. 37 - 40
Available at: http://works.bepress.com/xhuang/20/